Bone Therapeutics SA

Bone Therapeutics SA is a Belgium-based company that develops cell therapy products for treating and regenerating bone tissue and bone reconstruction applications. The company was founded in 2006 and has its headquarters in Mont-Saint-Guibert, Belgium. As of April 11, 2023, the company had a market cap of 17.98 million euros. Recently, Bone Therapeutics SA has changed its name to BioSenic following the acquisition of a majority participation of Medsenic valued at EUR 40 million.

The company's vision is to become a leader in cell therapy for bone diseases and to address unmet medical needs in orthopedics and other diseases. The company's leading product candidates are ALLOB, an allogeneic osteoblastic cell therapy product derived from bone marrow mesenchymal stem cells, and JTA-004, a protein solution for the treatment of osteoarthritis.

The company is currently conducting several clinical trials with its product candidates in various indications, such as difficult fractures, osteonecrosis, spinal fusion, knee osteoarthritis, and maxillo-facial reconstruction. The company also recently entered into exclusive reverse merger discussions with Medsenic, a privately held biopharmaceutical company specializing in developing arsenic salts for inflammatory conditions. The objective of the potential transaction is to create a fully integrated biopharmaceutical company with a diverse therapeutic portfolio targeting a broad array of inflammatory and orthopedic indications.

Bone Therapeutics SA is committed to advancing the field of cell therapy for bone diseases and to bringing innovative solutions to patients in need.

Foundation: 2006
Headquarters: Mont-Saint-Guibert, Belgium
Website: https://www.biosenic.com/